We are live on ! Find out more
VVM

Versant Venture Management Portfolio holdings

AUM $141M
1-Year Est. Return 190.82%
This Fund
S&P 500
This Quarter Est. Return
+19.17%
1 Year Est. Return
+190.82%
3 Year Est. Return
+375.7%
5 Year Est. Return
+81.85%
10 Year Est. Return
+4,735.29%
AUM
$343M
AUM Growth
+$39.6M
Cap. Flow
-$10.9M
Cap. Flow %
-3.18%
Top 10 Hldgs %
100%
Holding
10
New
1
Increased
–
Reduced
3
Closed
1

Top Buys

Rank Stock Value
1
GRTS
Gritstone bio, Inc. Common Stock
GRTS
+$35.5M

Top Sells

Rank Stock Value
1
VCYT icon
Veracyte
VCYT
+$30.1M
2
BOLD
Audentes Therapeutics, Inc
BOLD
+$9.57M
3
CBAY
Cymabay Therapeutics
CBAY
+$6.13M
4
AKAO
Achaogen Inc
AKAO
+$585K

Sector Composition

Rank Sector Weight
1 Healthcare 99.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRSP icon
1
CRISPR Therapeutics
CRSP
$4.68B
$200M 58.31%
4,248,888
– –
VCYT icon
2
Veracyte
VCYT
$4.44B
$68.7M 20.03%
2,410,815
-1,205,406
-33% -$30.1M
GRTS
3
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$34.6M 10.07%
+3,102,929
New +$35.5M
BOLD
4
DELISTED
Audentes Therapeutics, Inc
BOLD
$21M 6.11%
553,916
-249,190
-31% -$9.57M
OCUL icon
5
Ocular Therapeutix
OCUL
$1.85B
$9.75M 2.84%
2,215,384
– –
CBAY
6
DELISTED
Cymabay Therapeutics
CBAY
$3.89M 1.13%
543,753
-540,943
-50% -$6.13M
VANI icon
7
Vivani Medical
VANI
$113M
$3.6M 1.05%
187,207
– –
CLVS
8
DELISTED
Clovis Oncology, Inc.
CLVS
$1.51M 0.44%
101,855
– –
OPGN
9
DELISTED
OpGen, Inc
OPGN
$40.1K 0.01%
26
– –
AKAO
10
DELISTED
Achaogen Inc
AKAO
– –
-1,281,152
Closed -$585K

Similar funds

POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
RB
Renasant Bank Tupelo, Mississippi $141M AUM 16.9% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
CFGW
Chancellor Financial Group WB Wilkes-Barre, Pennsylvania $141M AUM 23.22% 1-Year Est. Return

Versant Venture Management's Q2 2019 Portfolio in Review

As of Q2 2019, Versant Venture Management held 10 positions worth $343M, up 13% from $304M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Versant Venture Management withdrew a net $10.9M in Q2 2019, closing 1 position and reducing 3 holdings. Its most notable exit was Achaogen Inc, an estimated $585K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, Versant Venture Management opened a new position in Gritstone bio, Inc. Common Stock worth $34.6M.

  • Versant Venture Management's largest Q2 2019 buy was Gritstone bio, Inc. Common Stock: 3,102,929 shares worth $34.6M.
  • Versant Venture Management's biggest Q2 2019 reduction was Veracyte, cutting an estimated $30.1M.
  • Versant Venture Management fully exited Achaogen Inc in Q2 2019, selling an estimated $585K.
  • Versant Venture Management's ten largest holdings make up 100% of its $343M portfolio in Q2 2019.
  • Versant Venture Management opened 1 new position and closed 1 in Q2 2019.
  • Versant Venture Management's portfolio value rose 13% quarter-over-quarter to $343M.

Based on Versant Venture Management's 13F filing for Q2 2019, filed 12 Jul 2019.